Time of day for vaccination, outcomes, and relative effectiveness of high-dose vs. standard-dose quadrivalent influenza vaccine: a post-hoc analysis of the DANFLU-1 randomized clinical trial

Time of day for vaccination, outcomes, and relative effectiveness of high-dose vs. standard-dose quadrivalent influenza vaccine: a post-hoc analysis of the DANFLU-1 randomized clinical trial

<p><b>Objectives</b></p> Morning influenza vaccination enhances antibody response. In this post hoc analysis of the DANFLU-1 trial, we sought to evaluate the association between time of day for vaccination (ToV) and outcomes and whether ToV modified the relative effectiveness...

Full description

Bibliographic Details
Main Authors:	Christensen, J, Johansen, ND, Janstrup, KH, Modin, D, Skaaru, KG, Nealon, J, Samson, S, Loiacono, M, Harris, R, Larsen, CS, Jensen, AMR, Landler, NE, Claggett, BL, Solomon, SD, Gislason, GH, Køber, L, Landray, MJ, Sivapalan, P, Jensen, JUS, Biering-Sørensen, T
Format:	Journal article
Language:	English
Published:	Elsevier 2024

Similar Items

Effects of high-dose versus standard-dose quadrivalent influenza vaccine among patients with diabetes: a post-hoc analysis of the DANFLU-1 trial
by: Lassen, MCH, et al.
Published: (2024)

Effectiveness of high-dose versus standard-dose quadrivalent influenza vaccine against recurrent hospitalizations and mortality in relation to influenza circulation: a post-hoc analysis of the DANFLU-1 randomized clinical trial
by: Johansen, ND, et al.
Published: (2024)

Feasibility of randomizing Danish citizens aged 65–79 years to high-dose quadrivalent influenza vaccine vs. standard-dose quadrivalent influenza vaccine in a pragmatic registry-based setting: rationale and design of the DANFLU-1 Trial
by: Niklas Dyrby Johansen, et al.
Published: (2022-04-01)

Feasibility of randomizing Danish citizens aged 65-79 years to high-dose quadrivalent influenza vaccine vs. standard-dose quadrivalent influenza vaccine in a pragmatic registry-based setting: rationale and design of the DANFLU-1 trial
by: Johansen, ND, et al.
Published: (2022)

A pragmatic randomized feasibility trial of influenza vaccines
by: Johansen, ND, et al.
Published: (2023)

Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate
by: Eliel Nham, et al.
Published: (2023-12-01)

An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population
by: Anna Fochesato, et al.
Published: (2022-08-01)

Cost-Effectiveness of Vaccination of Older Adults with an MF59<sup>®</sup>-Adjuvanted Quadrivalent Influenza Vaccine Compared to Standard-Dose and High-Dose Vaccines in Denmark, Norway, and Sweden
by: Jorge Jacob, et al.
Published: (2023-03-01)

Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain
by: Jesús Ruiz-Aragón, et al.
Published: (2022-01-01)

Cost-effectiveness for high dose quadrivalent versus the adjuvanted quadrivalent influenza vaccine in the Italian older adult population
by: Filippo Rumi, et al.
Published: (2023-11-01)

Immunogenicity of 2-dose pre-exposure rabies vaccine co-administered with quadrivalent influenza vaccine in children
by: Napaporn Chantasrisawad, et al.
Published: (2021-11-01)

Delayed dosing intervals for quadrivalent human papillomavirus vaccine do not reduce antibody avidity
by: Allison M. Brady, et al.
Published: (2020-08-01)

Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial
by: Stephanie Pepin, et al.
Published: (2021-12-01)

Reply letter to “Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial”
by: Sanjay Hadigal, et al.
Published: (2022-11-01)

Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later – an exploratory study
by: Vladimir Gilca, et al.
Published: (2019-02-01)

Immunogenicity and safety of the fourth dose of quadrivalent human papillomavirus (HPV) vaccine in immunosuppressed women who did not seroconvert after three doses
by: Lívia Zignago Moreira dos Santos, et al.
Published: (2024-12-01)

Cost-effectiveness and budget impact analysis for high dose quadrivalent influenza vaccine in the Italian elderly population
by: Filippo Rumi, et al.
Published: (2021-08-01)

Quadrivalent meningococcal conjugate vaccines
by: Pace, D, et al.
Published: (2009)

Quadrivalent meningococcal conjugate vaccines.
by: Pace, D, et al.
Published: (2009)

An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
by: Jesús Ruiz-Aragón, et al.
Published: (2023-02-01)

Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018–19 Influenza Season in the United States
by: Girishanthy Krishnarajah, et al.
Published: (2021-01-01)

Flu Vaccine and Mortality in Hypertension: A Nationwide Cohort Study
by: Daniel Modin, et al.
Published: (2022-03-01)

Immunogenicity and Safety of One versus Two Doses of Quadrivalent Inactivated Influenza Vaccine (IIV4) in Vaccine-Unprimed Children and One Dose of IIV4 in Vaccine-Primed Children Aged 3–8 Years
by: Yunfeng Shi, et al.
Published: (2023-10-01)

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany
by: Michele A. Kohli, et al.
Published: (2022-08-01)

The averted costs due to influenza vaccination with trivalent and quadrivalent vaccines
by: S. M. Kharit, et al.
Published: (2017-06-01)

Safety and Immunogenicity of Two Doses of Quadrivalent Meningococcal Conjugate Vaccine or One Dose of Meningococcal Group C Conjugate Vaccine, both Administered Concomitantly with Routine Immunization to 12- to 18-Month-Old Children
by: Francisco Noya, et al.
Published: (2014-01-01)

The feasibility of pragmatic influenza vaccine randomized controlled real-world trials in Denmark and England
by: Joshua Nealon, et al.
Published: (2022-02-01)

Quadrivalent inactivated influenza vaccine (VaxigripTetra™)
by: Viviane Gresset-Bourgeois, et al.
Published: (2018-01-01)

Enhanced passive safety surveillance of high-dose and standard-dose quadrivalent inactivated split-virion influenza vaccines in Germany and Finland during the 2022/23 influenza season
by: Marina Amaral de Avila Machado, et al.
Published: (2024-12-01)

AM/PM dosing of LAMA for COPD: a randomized controlled trial protocol using digital recruitment and registries
by: Pradeesh Sivapalan, et al.
Published: (2024-08-01)

Influenza burden averted with a cell-based quadrivalent seasonal influenza vaccine compared with egg-based quadrivalent seasonal influenza vaccine
by: Ian McGovern, et al.
Published: (2024-12-01)

Safety and immunogenicity of quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135) compared with quadrivalent meningococcal conjugate vaccine (Menactra®) in Malian children
by: Samba O. Sow, et al.
Published: (2023-08-01)

Impact of age at vaccination and cervical HPV infection status on binding and neutralizing antibody titers at 10 years after receiving single or higher doses of quadrivalent HPV vaccine
by: Neerja Bhatla, et al.
Published: (2023-12-01)

Immunogenicity and safety of high-dose quadrivalent influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial
by: Leilani Sanchez, et al.
Published: (2020-04-01)

Mosaic quadrivalent influenza vaccine single nanoparticle characterization
by: Rong Sylvie Yang, et al.
Published: (2024-02-01)

Current safety issues with quadrivalent meningococcal conjugate vaccines
by: Tanya R. Myers, et al.
Published: (2018-05-01)

Influenza vaccination: A case for removal of B/Yamagata from the quadrivalent vaccine
by: Parvaiz A Koul
Published: (2024-01-01)

Quadrivalent cell culture influenza virus vaccine. Comparison to egg-derived vaccine
by: Alberto Pérez-Rubio, et al.
Published: (2020-08-01)

Anamnestic immune response and safety of an inactivated quadrivalent influenza vaccine in primed versus vaccine-naïve children
by: Claeys, C, et al.
Published: (2018)

Immunogenicity and safety of Quadrivalent Influenza HA vaccine compared with Trivalent Influenza HA vaccine and evaluation of Quadrivalent Influenza HA vaccine batch-to-batch consistency in Indonesian children and adults.
by: Eddy Fadlyana, et al.
Published: (2023-01-01)